Abstract
Fractional exhaled nitric oxide (FeNO) is a type 2 inflammation marker used in the management of asthma. Current standards focus on thresholds to designate the presence and degree of local inflammation. However, epidemiological knowledge of FeNO values in general populations is needed to better understand the normal ranges and contributing factors.
In this analysis 3110 healthy probands without any history of respiratory diseases, atopy, inhaled medication use, current smoking, obstructive lung function and/or bronchial reversibility, aged 6-82 years with valid FeNO testing were included from the Austrian LEAD study, a single-centred, observational, longitudinal, general population cohort. The mean values and associations of FeNO with anthropometrics, non-respiratory diseases, history including symptoms, exposures, inflammatory parameters, allergy, and lung function were assessed.
FeNO levels were affected as seen in the stratification and stepwise linear regression analyses:
Our data elucidate the considerable distribution of FeNO in both youth and adults of a large, respiratory healthy population, which is affected by factors like age, height, eosinophils, and lung function.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4523.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
